Vaginal dryness, loss of libido, and pain during sex are some of the most common sexual side effects of hormonal therapy to treat hormone-receptor-positive breast cancer. Still, a small study suggests that postmenopausal women with partners may have better quality of life than women without partners when experiencing a number of sexual side effects from breast cancer hormonal therapy. The research was published online on April 15,by the journal Menopause.
After diagnosis and during treatment, fatigue and other side effects caused by therapy, as well as depression — engrafted on pre-existing and ongoing work and family roles — often serve to decrease or negate sexual desire. Cancer can be detrimental to female sexual functioning when organs such as the breast, cervix, uterus and vulva undergo surgery or radiotherapy. As an example, placing radiation cylinders into the vagina may cause the organ to shorten and narrow.
Now a new study suggests these problems are even more common among women who have had breast cancer. In fact, 7 in 10 breast cancer survivors experience sexual problems in the two years after their diagnosis, according to the study, published this week in the Journal of Sexual Medicine. Sexual problems after breast cancer treatment are "a hidden issue that women have a real reluctance to discuss," says Dr.
Jump to content. A woman's sex organs are on both the inside uterus, cervix, and ovaries and outside of the body vulva. The breasts, nipples, and other areas of the body can also be sensitive to touch. When you are sexually aroused, your body goes through different stages.
The study by Dr. Finkelstein and his colleagues answers important questions but raises new questions as well, said Dr. David J.
Pronounced: an-AS-troe-zole. Classification: aromatase inhibitor. Anastrozole is an aromatase inhibitor, which works to decrease the overall levels of estrogen in a woman's body.
Chemotherapy, or chemo, is often given through an intravenous IV tube, which sends it through a vein right into the bloodstream. But sometimes the drugs are sent right to the tumor. For cancer of the bladder, for example, the chemo drug is put right into the bladder through a small, soft tube called a catheter.
Treatment with aromatase inhibitors for postmenopausal women with breast cancer has been shown to reduce or obviate invasive procedures such as hysteroscopy or curettage associated with tamoxifen-induced endometrial abnormalities. The side effect of upfront aromatase inhibitors, diminished estrogen synthesis, is similar to that seen with the natural events of aging. The consequences often include vasomotor symptoms hot flushes and vaginal dryness and atrophy, which in turn may result in cystitis and vaginitis.
SAN ANTONIO — Postmenopausal women with hormone-receptor positive HR-positive breast cancer who took the aromatase inhibitor anastrozole for two years after an initial five years of adjuvant endocrine therapy received an equal benefit to those who took the drug for five additional years. The trial results suggest that a shorter duration of treatment may provide sufficient benefits while protecting women from harmful side effects, according to data from the ABCSG phase III trial presented at the San Antonio Breast Cancer Symposiumheld Dec. However, the optimal duration of extended AI has previously been unknown.
NEW YORK Reuters Health - Women treated with hormone-blocking drugs to stave off breast cancer recurrences are often dissatisfied with their sex lives, a new study from Sweden has found. More than half of older women treated with so-called aromatase inhibitors said sex was almost always painful and they frequently had "insufficient lubrication," researchers reported in the journal Menopause. In contrast, less than one-third of women on tamoxifen, another anti-estrogen drug, reported painful sex. Don Dizon, a gynecologic oncologist from Massachusetts General Hospital in Boston who has studied sexual health in cancer survivors.